Companies › Solstice Oncology
1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Sep 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Porustobart Toll-like receptor 8 (TLR8) agonist | TLR8 | Phase 2 | Colon Cancer | Sep 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07808151 | Porustobart | Phase 2 | Colon Cancer | Oncology | Sep 2029 |
Merck KGaA Eikon Therapeutics United Immunity Beeline Medicines HighField Biopharmaceuticals Ascendis Pharma Oncology Division Bolt Biotherapeutics Inimmune
CatalYm Alethia Biotherapeutics CrystalGenomics Partner Therapeutics STCube
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.